Clinical Trials
275 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
SAMETA
AstraZeneca
TroFuse-019
Merck Sharp & Dohme LLC
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
INDIGO
Boston Scientific Corporation
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
TROPION-Lung15
AstraZeneca
DG-03
AstraZeneca
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
LITESPARK-033
Merck Sharp & Dohme LLC
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
HIVEC
AC.TA. S.r.l.
ROWAN
Boston Scientific Corporation
SAVANNAH
AstraZeneca
ARTACUS
Replimune, Inc.
Be6A Lung-02
Pfizer
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
Novartis
SAFFRON
AstraZeneca
REZILIENT2
Taiho Oncology, Inc.
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Pfizer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
ToLymph Inc.
AcceleRET-Lung
Hoffmann-La Roche
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
CoC
AstraZeneca
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
KEYLYNK-008
Merck Sharp & Dohme LLC
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Boehringer Ingelheim
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Auricula Biosciences Inc.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
FORTIFY
Akamis Bio
COSMIC-312
Exelixis
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Adaptimmune
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
ADRIATIC
AstraZeneca
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
FLAURA2
AstraZeneca
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
Sichuan Baili Pharmaceutical Co., Ltd.